{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:19:41Z","timestamp":1777317581006,"version":"3.51.4"},"reference-count":97,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.breast.2013.07.045","type":"journal-article","created":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T04:01:53Z","timestamp":1377057713000},"page":"561-568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Breast cancer in women at high risk: The role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies"],"prefix":"10.1016","volume":"22","author":[{"given":"Anne Brecht","family":"Francken","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip C.","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eveline M.A.","family":"Bleiker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine C.","family":"Linn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiel J.Th.","family":"Rutgers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.breast.2013.07.045_bib1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","article-title":"Estimates of cancer incidence and mortality in Europe in 2008","volume":"46","author":"Ferlay","year":"2010","journal-title":"Eur J Cancer"},{"issue":"24","key":"10.1016\/j.breast.2013.07.045_bib2","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/jnci\/djq443","article-title":"Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations","volume":"102","author":"Metcalfe","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.breast.2013.07.045_bib3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.breast.2008.05.001","article-title":"Counseling for male BRCA mutation carriers: a review","volume":"17","author":"Mohamad","year":"2008","journal-title":"Breast"},{"issue":"5","key":"10.1016\/j.breast.2013.07.045_bib4","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.breast.2013.07.045_bib5","first-page":"272","article-title":"Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40","volume":"14","author":"Ardern-Jones","year":"2005","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"3","key":"10.1016\/j.breast.2013.07.045_bib6","first-page":"369","article-title":"BRCA testing of breast cancer patients: medical specialists' referral patterns, knowledge and attitudes to genetic testing","volume":"19","author":"Van Riel","year":"2010","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"11","key":"10.1016\/j.breast.2013.07.045_bib7","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/jnci\/94.11.844","article-title":"Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO","volume":"94","author":"Euhus","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.breast.2013.07.045_bib8","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/sj.bjc.6602175","article-title":"The BOADICEA model of genetic susceptibility to breast and ovarian cancer","volume":"91","author":"Antoniou","year":"2004","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.breast.2013.07.045_bib9","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2007.04.023","article-title":"Genetic epidemiology of BRCA mutations\u2013family history detects less than 50% of the mutation carriers","volume":"43","author":"Moller","year":"2007","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.breast.2013.07.045_bib10","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ijc.11271","article-title":"Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study","volume":"106","author":"de Sanjose","year":"2003","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.breast.2013.07.045_bib11","doi-asserted-by":"crossref","first-page":"I47","DOI":"10.7326\/0003-4819-143-5-200509060-00005","article-title":"Summaries for patients. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: U.S. Preventive Services Task Force recommendations","volume":"143","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.breast.2013.07.045_bib12","series-title":"Richtlijn mammacarcinoom","year":"2012"},{"key":"10.1016\/j.breast.2013.07.045_bib13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2407-9-86","article-title":"The prevalence of BRCA1 mutations among young women with triple-negative breast cancer","volume":"9","author":"Young","year":"2009","journal-title":"BMC Cancer"},{"issue":"15","key":"10.1016\/j.breast.2013.07.045_bib14","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","article-title":"Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium","volume":"91","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.breast.2013.07.045_bib15","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","article-title":"Cancer Incidence in BRCA1 mutation carriers","volume":"94","author":"Thompson","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.breast.2013.07.045_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/B:FAME.0000026816.32400.45","article-title":"Cancer variation associated with the position of the mutation in the BRCA2 gene","volume":"3","author":"Lubinski","year":"2004","journal-title":"Fam Cancer"},{"issue":"4","key":"10.1016\/j.breast.2013.07.045_bib17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2004.05.055","article-title":"Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature","volume":"22","author":"Liede","year":"2004","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.breast.2013.07.045_bib18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/jmg.2004.028829","article-title":"Cancer risks in BRCA2 families: estimates for sites other than breast and ovary","volume":"42","author":"van Asperen","year":"2005","journal-title":"J Med Genet"},{"issue":"12","key":"10.1016\/j.breast.2013.07.045_bib19","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1245\/s10434-009-0638-7","article-title":"Breast-conserving surgery in BRCA1\/2 mutation carriers: are we approaching an answer?","volume":"16","author":"Garcia-Etienne","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"9316","key":"10.1016\/j.breast.2013.07.045_bib20","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/S0140-6736(02)08434-9","article-title":"Outcome of conservatively managed early-onset breast cancer by BRCA1\/2 status","volume":"359","author":"Haffty","year":"2002","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.breast.2013.07.045_bib21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/annonc\/mdj095","article-title":"Survival and prognostic factors in BRCA1-associated breast cancer","volume":"17","author":"Brekelmans","year":"2006","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.breast.2013.07.045_bib22","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.2005.02.7888","article-title":"Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1\/2-associated stage I\/II breast cancer","volume":"24","author":"Pierce","year":"2006","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.breast.2013.07.045_bib23","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2000.18.19.3360","article-title":"Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1\/2 mutations","volume":"18","author":"Pierce","year":"2000","journal-title":"J Clin Oncol"},{"issue":"9099","key":"10.1016\/j.breast.2013.07.045_bib24","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0140-6736(97)07065-7","article-title":"Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1","volume":"351","author":"Verhoog","year":"1998","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.breast.2013.07.045_bib25","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrclinonc.2010.175","article-title":"The role of BRCA mutation testing in determining breast cancer therapy","volume":"7","author":"Trainer","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"15","key":"10.1016\/j.breast.2013.07.045_bib26","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.ejca.2005.02.037","article-title":"Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy","volume":"41","author":"Kirova","year":"2005","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.breast.2013.07.045_bib27","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-010-0894-z","article-title":"Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy","volume":"121","author":"Pierce","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2013.07.045_bib28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10549-010-1336-7","article-title":"Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"127","author":"Metcalfe","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.breast.2013.07.045_bib29","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1200\/JCO.2004.04.033","article-title":"Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"22","author":"Metcalfe","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2013.07.045_bib30","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1054\/bjoc.2000.1239","article-title":"Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer","volume":"83","author":"Verhoog","year":"2000","journal-title":"Br J Cancer"},{"issue":"14","key":"10.1016\/j.breast.2013.07.045_bib31","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1200\/JCO.2009.24.2495","article-title":"Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2","volume":"28","author":"Malone","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2013.07.045_bib32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJM200107193450301","article-title":"Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation","volume":"345","author":"Meijers-Heijboer","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.breast.2013.07.045_bib33","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.bjc.6602703","article-title":"Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers","volume":"93","author":"van Sprundel","year":"2005","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.breast.2013.07.045_bib34","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1200\/JCO.2007.12.6078","article-title":"Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group","volume":"26","author":"Metcalfe","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2013.07.045_bib35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/jnci\/djq018","article-title":"Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients","volume":"102","author":"Bedrosian","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.breast.2013.07.045_bib36","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.breast.2013.07.045_bib37","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1055-9965.EPI-03-0545","article-title":"Utilization of BRCA1\/BRCA2 mutation testing in newly diagnosed breast cancer patients","volume":"14","author":"Schwartz","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"12","key":"10.1016\/j.breast.2013.07.045_bib38","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/archsurg.138.12.1323","article-title":"Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis","volume":"138","author":"Weitzel","year":"2003","journal-title":"Arch Surg"},{"issue":"33","key":"10.1016\/j.breast.2013.07.045_bib39","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1200\/JCO.2007.12.3141","article-title":"Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment","volume":"25","author":"Tuttle","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2013.07.045_bib40","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1245\/s10434-009-0362-3","article-title":"Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy","volume":"16","author":"Sorbero","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"16","key":"10.1016\/j.breast.2013.07.045_bib41","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1200\/JCO.2010.29.4041","article-title":"Clinical management factors contribute to the decision for contralateral prophylactic mastectomy","volume":"29","author":"King","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2013.07.045_bib42","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10549-010-0769-3","article-title":"Adjuvant systemic therapy for breast cancer in BRCA1\/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer","volume":"123","author":"Reding","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2013.07.045_bib43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/jnci\/djm267","article-title":"Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study","volume":"100","author":"Bertelsen","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"10.1016\/j.breast.2013.07.045_bib44","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/jnci\/89.22.1673","article-title":"Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer","volume":"89","author":"Fisher","year":"1997","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"10.1016\/j.breast.2013.07.045_bib45","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.ejca.2009.05.022","article-title":"Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial","volume":"45","author":"Alkner","year":"2009","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.breast.2013.07.045_bib46","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/ijc.21536","article-title":"Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update","volume":"118","author":"Gronwald","year":"2006","journal-title":"Int J Cancer"},{"issue":"Suppl 6","key":"10.1016\/j.breast.2013.07.045_bib47","doi-asserted-by":"crossref","first-page":"vi31","DOI":"10.1093\/annonc\/mdr373","article-title":"BRCA in breast cancer: ESMO Clinical Practice Guidelines","volume":"22","author":"Balmana","year":"2011","journal-title":"Ann Oncol"},{"issue":"31","key":"10.1016\/j.breast.2013.07.045_bib48","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1200\/JCO.2007.11.0379","article-title":"Reducing second breast cancers: a potential role for prophylactic mammary irradiation","volume":"25","author":"Brenner","year":"2007","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.breast.2013.07.045_bib49","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1200\/JCO.2009.27.2294","article-title":"BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study","volume":"28","author":"Rijnsburger","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2013.07.045_bib50","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ejca.2006.12.009","article-title":"Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-","volume":"43","author":"Brekelmans","year":"2007","journal-title":"B. Eur J Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.breast.2013.07.045_bib51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0959-8049(09)70012-7","article-title":"'t Veer LJ. Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept","volume":"45","author":"Linn","year":"2009","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.breast.2013.07.045_bib52","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of 'BRCAness' in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.breast.2013.07.045_bib53","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: different roles in a common pathway of genome protection","volume":"12","author":"Roy","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"Suppl 6","key":"10.1016\/j.breast.2013.07.045_bib54","doi-asserted-by":"crossref","first-page":"vi12","DOI":"10.1093\/annonc\/mdr371","article-title":"Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"22","author":"Aebi","year":"2011","journal-title":"Ann Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.breast.2013.07.045_bib55","doi-asserted-by":"crossref","first-page":"vii11","DOI":"10.1093\/annonc\/mds232","article-title":"Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Cardoso","year":"2012","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.breast.2013.07.045_bib56","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrc3088","article-title":"DNA interstrand crosslink repair and cancer","volume":"11","author":"Deans","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.breast.2013.07.045_bib57","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/carcin\/bgq064","article-title":"Homologous recombination in cancer development, treatment and development of drug resistance","volume":"31","author":"Helleday","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.breast.2013.07.045_bib58","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev.pathol.3.121806.151422","article-title":"Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment","volume":"4","author":"Venkitaraman","year":"2009","journal-title":"Annu Rev Pathol"},{"issue":"22","key":"10.1016\/j.breast.2013.07.045_bib59","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","article-title":"A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair","volume":"26","author":"Ashworth","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7035","key":"10.1016\/j.breast.2013.07.045_bib60","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.breast.2013.07.045_bib61","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1136\/jmg.39.8.608","article-title":"A significant response to neoadjuvant chemotherapy in BRCA1\/2 related breast cancer","volume":"39","author":"Chappuis","year":"2002","journal-title":"J Med Genet"},{"issue":"14","key":"10.1016\/j.breast.2013.07.045_bib62","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1002\/cncr.25911","article-title":"Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers","volume":"117","author":"Lee","year":"2011","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.breast.2013.07.045_bib63","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10689-008-9223-7","article-title":"Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer","volume":"8","author":"Hubert","year":"2009","journal-title":"Fam Cancer"},{"issue":"23","key":"10.1016\/j.breast.2013.07.045_bib64","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1200\/JCO.2008.19.9067","article-title":"Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"27","author":"Kriege","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2013.07.045_bib65","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/COC.0b013e31817f9e1c","article-title":"Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1\/2 mutations status","volume":"32","author":"Fourquet","year":"2009","journal-title":"Am J Clin Oncol"},{"issue":"9","key":"10.1016\/j.breast.2013.07.045_bib66","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1002\/ijc.24596","article-title":"Long-term outcome after neo-adjuvant chemotherapy for breast cancer in BRCA1\/2 carriers","volume":"125","author":"Wong Wong","year":"2009","journal-title":"Int J Cancer"},{"issue":"28","key":"10.1016\/j.breast.2013.07.045_bib67","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1200\/JCO.2011.35.2682","article-title":"Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience","volume":"29","author":"Arun","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.breast.2013.07.045_bib68","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.26351","article-title":"The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"118","author":"Kriege","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.breast.2013.07.045_bib69","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/bcr3231","article-title":"Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer","volume":"14","author":"Byrski","year":"2012","journal-title":"Breast Cancer Res"},{"issue":"7","key":"10.1016\/j.breast.2013.07.045_bib70","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","article-title":"Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer","volume":"28","author":"Silver","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2013.07.045_bib71","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-008-0128-9","article-title":"Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients","volume":"115","author":"Byrski","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.breast.2013.07.045_bib72","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.breast.2013.07.045_bib73","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/path.4140","article-title":"Secondary Mutations in BRCA2 Associated with Clinical Resistance to a PARP inhibitor","volume":"229","author":"Barber","year":"2013","journal-title":"J Pathol"},{"issue":"9","key":"10.1016\/j.breast.2013.07.045_bib74","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"issue":"9737","key":"10.1016\/j.breast.2013.07.045_bib75","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.breast.2013.07.045_bib76","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2008.20.7019","article-title":"Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy","volume":"28","author":"Byrski","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2013.07.045_bib77","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10549-007-9600-1","article-title":"Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers","volume":"108","author":"Byrski","year":"2008","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2013.07.045_bib78","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1186\/bcr658","article-title":"A combined analysis of outcome following breast cancer: differences in survival based on BRCA1\/BRCA2 mutation status and administration of adjuvant treatment","volume":"6","author":"Robson","year":"2004","journal-title":"Breast Cancer Res"},{"issue":"9","key":"10.1016\/j.breast.2013.07.045_bib79","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrclinonc.2012.121","article-title":"Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?","volume":"9","author":"Beelen","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2013.07.045_bib80","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00018-011-0809-0","article-title":"Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers","volume":"69","author":"Vollebergh","year":"2012","journal-title":"Cell Mol Life Sci"},{"issue":"9","key":"10.1016\/j.breast.2013.07.045_bib81","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2005.01.112","article-title":"Clinical trial designs for predictive marker validation in cancer treatment trials","volume":"23","author":"Sargent","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2013.07.045_bib82","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ccr.2011.11.014","article-title":"BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance","volume":"20","author":"Drost","year":"2011","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.breast.2013.07.045_bib83","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1349-7006.2010.01840.x","article-title":"Secondary mutations of BRCA1\/2 and drug resistance","volume":"102","author":"Dhillon","year":"2011","journal-title":"Cancer Sci"},{"issue":"7","key":"10.1016\/j.breast.2013.07.045_bib84","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/annonc\/mdq624","article-title":"An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients","volume":"22","author":"Vollebergh","year":"2011","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.breast.2013.07.045_bib85","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.2002.20.2.514","article-title":"Impact of BRCA1\/BRCA2 mutation testing on psychologic distress in a clinic-based sample","volume":"20","author":"Schwartz","year":"2002","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2013.07.045_bib86","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1075-122X.2004.21543.x","article-title":"Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation","volume":"10","author":"Stolier","year":"2004","journal-title":"Breast J"},{"issue":"2","key":"10.1016\/j.breast.2013.07.045_bib87","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/jnci\/djh017","article-title":"Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis","volume":"96","author":"Braithwaite","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.breast.2013.07.045_bib88","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/cncr.26294","article-title":"Long-term outcomes of BRCA1\/BRCA2 testing: risk reduction and surveillance","volume":"118","author":"Schwartz","year":"2012","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.breast.2013.07.045_bib89","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1200\/JCO.2004.02.994","article-title":"Tailoring breast cancer treatment to genetic status: the challenges ahead","volume":"22","author":"Daly","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2013.07.045_bib90","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pec.2012.03.019","article-title":"Breast cancer genetic counseling after diagnosis but before treatment: a pilot study on treatment consequences and psychological impact","volume":"89","author":"Wevers","year":"2012","journal-title":"Patient Educ Couns"},{"issue":"11","key":"10.1016\/j.breast.2013.07.045_bib91","first-page":"2949","article-title":"Are we being overly cautious? A qualitative inquiry into the experiences and perceptions of treatment-focused germline BRCA genetic testing amongst women recently diagnosed with breast cancer","volume":"20","author":"Zilliacus","year":"2012","journal-title":"Support Care Cancer"},{"issue":"7","key":"10.1016\/j.breast.2013.07.045_bib92","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1245\/s10434-009-0479-4","article-title":"Recall of and reactions to a surgeon referral letter for BRCA genetic counseling among high-risk breast cancer patients","volume":"16","author":"Vadaparampil","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.breast.2013.07.045_bib93","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2407-11-6","article-title":"Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial","volume":"11","author":"Wevers","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2013.07.045_bib94","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/1471-2407-12-320","volume":"12","author":"Watts","year":"2012","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.breast.2013.07.045_bib95","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.2006.07.3890","article-title":"Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1\/2 gene testing","volume":"25","author":"Tercyak","year":"2007","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.breast.2013.07.045_bib96","doi-asserted-by":"crossref","first-page":"7849","DOI":"10.1200\/JCO.2005.09.233","article-title":"Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance","volume":"23","author":"Frost","year":"2005","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.breast.2013.07.045_bib97","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1002\/cncr.25971","article-title":"Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer","volume":"117","author":"Le-Petross","year":"2011","journal-title":"Cancer"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977613002105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977613002105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:30:03Z","timestamp":1760776203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977613002105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":97,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0960977613002105"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2013.07.045","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breast cancer in women at high risk: The role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2013.07.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}